Post-liver transplant obesity and XXXX .

@entity1 @entity6 @entity28 @entity2299 @entity205 @entity1140 @entity65
PURPOSE OF REVIEW: Post-liver transplant @entity1 present a vast array of metabolic changes in the early and late phase which impact on their morbidity and mortality. The development of @entity28 and @entity6 in these @entity1 has been widely described in the literature with several hypotheses suggested: liver donor, nutritional and metabolic state, and immunosuppressive drugs. RECENT FINDINGS: Most that is known about the development of these metabolic derangements has been attributed to the drugs used, especially the corticosteroids. When these have been used in higher doses for longer periods to treat rejection, the incidence of @entity6 and @entity28 seems to be higher. However @entity205 and to a lesser extent @entity1140 are also related to these alterations. SUMMARY: As long-term survival improves in liver transplant @entity1 , @entity65 associated with @entity2299 , @entity28 , and @entity6 are emerging as risk factors for late morbidity and mortality. Therefore, it is important to assess the potential risk factors related to these complications, in order to prevent or decrease their incidence. From what has been seen, immunossupressive drugs seem to be the greatest risk factor for the development of metabolic derangements in post-transplantation @entity1 . However other risk factors might also be involved, such as non-healthy eating habits and lack of exercise. The latter can be preventable if counseling policies are targeted at these @entity1 in the pre-transplantation phase and continued after the operation.
